



DOTTIKON ES' Shareholders Approve all Proposals of the Board of Directors

Dottikon, Switzerland, July 1, 2011 – At the 6th Annual General Meeting of DOTTIKON ES HOLDING AG for the business year 2010/11 carried out at the "Kultur- und Kongresszentrum TRAFO" in Baden, the shareholders approved all proposals of the Board of Directors. 85 present shareholders represented 1'103'549 voting rights and therefore 91.6% of the total of 1'205'299 registered shares with voting rights.

The Annual Report, financial statements 2010/11 and the consolidated financial statements 2010/11 of DOTTIKON ES HOLDING AG were approved by the Annual General Meeting. Further the proposal of the Board of Directors to carry forward the entire retained earnings to new account and pay no dividend was accepted. Discharge for the business year 2010/11 was granted to the responsible Board of Directors and Management. Members of the Board Heinz Boller, Dr. h.c. Peter Grogg and Dr. Markus Blocher are reelected, and Dr. Alfred Scheidegger as additional member newly appointed to the Board, all for a term of one year. Statutory auditor for an additional term of one year is KPMG AG, Zurich.

DOTTIKON ES, with its production site in Dottikon (Aargau, Switzerland), is specialized in hazardous chemical reactions and focuses on the exclusive synthesis of fine chemicals for the pharmaceutical and chemical industry worldwide. The product range of DOTTIKON ES includes active pharmaceutical ingredients (APIs) and pharmaceutical intermediates as well as in-house-developed, high-value industrial chemicals.

DOTTIKON ES HOLDING AG is listed at the SIX Swiss Exchange.

Symbol: DESN

Security number: 2073900

ISIN: CH0020739006

For further information please contact

Markus Blocher, Ph.D.
CEO

Dottikon ES Holding AG
Tel +41 56 616 82 01
Fax +41 56 616 89 45
investor-relations@dottikon.com